Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / Jan / Also in the News… (1)
Research & Innovations Anterior Segment Cornea Glaucoma Retina

Also in the News…

From keratoconus NDAs to gut microbiota links to retinal vein occlusion, these are the news stories and studies that caught our attention this week…

By Alun Evans 1/17/2025 1 min read

Share

Zhangmoon618, CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0, via Wikimedia Commons

New keratoconus drug submission. Glaukos has submitted a New Drug Application (NDA) for Epioxa (Epi-on), a next-generation corneal cross-linking keratoconus treatment. The company hopes the NDA submission will bring it closer to providing the first FDA-approved, non-invasive corneal cross-linking drug therapy for keratoconus that doesn’t require corneal epithelium removal. Link

Lumenis training. Three out of four optometry students in the US will now be trained in Lumenis’ intense pulsed light (IPL) dry eye management therapies, the company reports. Lumenis is introducing its OptiLIGHT and OptiPLUS technologies into universities across the country, in the hope that optometrists will enter the profession ready to integrate IPL into their everyday practice. Link

Glaucoma UK research grants. Glaucoma UK has launched its research program for 2025. It is the largest ever funding round for the charity, with a total of £370,000 to be awarded. The submission deadline is April 1, with decisions announced in June. Apply here

AMD and heart disease. An Ophthalmology Science study has revealed a significant link between age-related macular degeneration (AMD) and an increased risk of valvular heart disease (VHD). Patients with AMD showed higher rates of VHD and related procedures, regardless of AMD subtype, suggesting shared risk factors like aging and inflammation. The findings emphasize the need for cross-disciplinary care and the use of cardiovascular data to improve AMD diagnosis and management. Link

DME survey. A global survey on diabetic macular edema (DME) has highlighted key barriers that can impact patients’ management of the disease. Patients and providers surveyed emphasized the need for better communication, reduced appointment burdens, and improved infrastructure to enhance care delivery. The survey findings highlight the need for more holistic, patient-centered strategies – and use of innovative technologies – to improve outcomes and transform DME management worldwide. Link

Gut feeling. A TVST study has identified that six gut microbiota taxa, including Bacilli and Lactobacillales, are significantly associated with retinal vein occlusion (RVO). Using Mendelian randomization and genetic analysis, the researchers – based at Wuhan No.1 Hospital, China – found a genetic overlap between these microbiota and RVO, suggesting that gut microbiota could be an influencing factor in retinal vascular health. Link

About the Author(s)

Alun Evans

More Articles by Alun Evans

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: